Vicore Pharma Posts Q2 Loss, Completes ASPIRE Enrollment, and Extends Cash Runway to 2028
VCRE sits 19% above its 52-week low of $10.5 on light trading volume (0.1× avg).
Summary
Vicore Pharma reported a SEK 142.8M net loss for Q2 2026, completed enrollment in its Phase 2b ASPIRE trial, and extended cash runway into 2028.
Key Events · Earnings and Guidance · VCRE
-
Q2 2026 Financial Results
Operating loss widened to SEK 150.1M from SEK 111.2M in Q2 2025; net loss was SEK 142.8M. R&D expenses rose to SEK 118.9M, reflecting increased investment in the ASPIRE trial.
-
ASPIRE Trial Enrollment Completed
Patient recruitment in the Phase 2b ASPIRE trial for buloxibutid in IPF was completed ahead of schedule with over 360 patients across 14 countries. Topline data expected mid-2027.
-
Cash Runway Extended to 2028
Cash, cash equivalents, and short-term investments totaled SEK 905.6M (USD 93.0M) as of June 30, 2026, providing runway into the second half of 2028.
-
Nasdaq Dual Listing
American Depositary Shares commenced trading on Nasdaq Capital Market under ticker VCRE in July 2026, complementing the existing Nasdaq Stockholm listing.
Analysis · VCRE · Life Sciences
The Q2 2026 report reveals a widening operating loss of SEK 150.1 million, driven by increased R&D spending on the Phase 2b ASPIRE trial in IPF. Enrollment finished ahead of schedule with over 360 patients, setting the stage for topline data in mid-2027. With SEK 905.6 million in cash, the runway extends into the second half of 2028, removing near-term financing risk. The Nasdaq dual listing and new CSO appointment bolster the company's US presence and scientific leadership ahead of the pivotal readout.
At the time of this filing, VCRE was trading at $12.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $326.3M. The 52-week trading range was $10.50 to $17.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.